Do HMG-CoA Reductase Inhibitors Affect Fibrinogen?

Abstract

OBJECTIVE:

To review commonly used fibrinogen assay methods and the evidence demonstrating an association between fibrinogen and increased risk of coronary artery disease and to review the current literature to determine and assess the impact of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on fibrinogen.

DATA SOURCES:

Primary and review articles identified from a MEDLINE search (1966–December 1999); references obtained from these publications were subsequently reviewed for additional relevant articles.

STUDY SELECTION AND DATA EXTRACTION:

All articles were evaluated, and all relevant information was included in this review.

DATA SYNTHESIS:

The Clauss method is currently the preferred method for determining plasma fibrinogen concentrations, due to its high degree of accuracy and precision. Furthermore, unlike immunologic methods, its reliability is unaffected by change in triglycerides. The effects of four HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin, pravastatin) on fibrinogen have been evaluated. Atorvastatin has been shown to induce significant increases in fibrinogen (22% increase; p < 0.05) by using the mmunonephelometric method. This method also demonstrated that lovastatin use was associated with a 24.4% increase (p < 0.0001) in plasma fibrinogen concentration. Simvastatin has been shown in multiple studies using the Clauss method to have a neutral effect on fibrinogen. The majority of studies have revealed significant decreases (7–19%) in fibrinogen following treatment with pravastatin.

CONCLUSIONS:

Future studies need to be performed evaluating the effects of HMG-CoA reductase inhibitors on fibrinogen, but using direct comparisons and clotting assay methodology.